Case-Based Discussions on the Corneal Nerve in Ocular Surface Disease (CE Webcast)

Activity Description and Purpose

Corneal nerves have an essential role in maintaining ocular surface health and homeostasis. Manifestations of neurosensory abnormalities affecting corneal innervation include dry eye disease and neurotrophic keratopathy. These conditions can exist as a standalone entity, but they can also be concurrent and have overlapping features, making diagnosis challenging. Early diagnosis is important to allow intervention that can help to restore function and improve quality of life. This educational activity includes real-world cases and discussion on diagnostic modalities used to identify these conditions and options for treatment. The desired results of this educational activity are to familiarize optometrists with the role of the corneal nerve in maintaining ocular surface homeostasis and practical strategies for screening and diagnosing of ocular surface disease that can arise as the result of corneal nerve dysfunction.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review diagnostic modalities used for proper assessment of ocular surface disease
  • Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
Course summary
Available credit: 
  • 1.00 COPE
Course opens: 
09/15/2023
Course expires: 
09/30/2024

Faculty

Douglas K. Devries, OD (Co-Chair)
Associate Clinical Professor
Pacific University College of Optometry
Co-Founder
Advanced Vision and Laser Center
Reno, Nevada

Kendall E. Donaldson, MD, MS (Co-Chair)
Professor of Clinical Ophthalmology
Medical Director
Bascom Palmer Eye Institute in Plantation
Plantation, Florida

 

Jaclyn Garlich, OD
Owner
Envision Optometry
Boston, Massachusetts

Christopher E. Starr, MD, FACS
Associate Professor of Ophthalmology
Director, Refractive Surgery Service
Director, Ophthalmic Education
Weill Cornell Medicine
New York, New York

Disclosure Policy

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company. All relevant relationships with ineligible companies have been mitigated.

Faculty

Douglas K. Devries, OD, is a consultant for Alcon, Allergan, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, and Visus Therapeutics; and is on the speakers bureau of Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Kala Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.

Kendall E. Donaldson, MD, MS, is a consultant for AcuFocus, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Omeros Corporation, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Zeiss.

Jaclyn Garlich, OD, is a consultant for Lumenis; and is an advisory board member of Allergan, Bruder Healthcare, Dompé US, Inc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited.

Christopher E. Starr, MD, is a consultant for Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Allergan, Bruder Healthcare, Dompé US, Inc, EyeBio, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Quidel Corporation, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, and Verséa Health, Inc; and has individual stocks and stock options in Èssiri Labs.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 86936-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease

Administrator:

This activity, COPE Activity Number 126783, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.

The content of this COPE-Accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.

This CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 266.3

Available Credit

  • 1.00 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.